ARTICLE | Company News
PDT other research news
June 24, 1996 7:00 AM UTC
PDTI received a $100,000 Phase I SBIR grant from the National Eye Institute to develop the company's SnET2 light-activated drug to treat glaucoma. PDTI is developing SnET2 to control increased pressur...